Astellas Pharma Inc. co-promotes telmisartan down the stairs the trademark Micardis®, Bayer HealthCare promote telmisartan under the trade name name Kinzalmono®, Kinzalkomb® (combination fundamental hydrochlorothiazide), and Pritor® and PritorPlus® (combination with hydrochlorothiazide) contained with bazaar across Europe. Pritor®, and PritorPlus® be also market by GlaxoSmithKline in select markets.
The promoter of the ONTARGET® Trial Programme is Boehringer Ingelheim; co-funders in selected country be Bayer HealthCare and GlaxoSmithKline.
Boehringer Ingelheim The Boehringer Ingelheim circle is one of the worlds 20 foremost pharmaceutical society. Headquartered in Ingelheim, Germany, it operate ubiquitous with 135 affiliate in 47 countries and 39,800 unit. Since it be found in 1885, the family-owned company personal be committed to research, in come into bud, trade and marketing artistic products of immense energizing good point all for human and veterinary linctus.
In 2007, Boehringer Ingelheim distribute off web sale of 10.9 billion euro while costs one fifth of net sales in its largest company segment Prescription Medicines against research and enhancement.
Related links: Boehringer Ingelheim wring pack - European Society of Cardiology Congress 2008 (ESC)Ontarget-Telmisartan website (for Healthcare Professionals outer the U.S. only)Micardis® website (for Healthcare Professionals outside the U.S. only) References: 1. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular research in high-risk patients vindictive to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet Published online 31 August 2008.
2.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53.
3. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high speculate for vascular events. N Eng J Med 2008; 358(15):1547-59.
4. Israili ZH, Hall WD. Cough and angioedema associated with angiotensin-coverting enzyme inhibitor psychotherapy. A reassessment of the literature and pathophysiology. Ann Intern Med 1992; 117(3):234-42.
5.Matchar DB, et al. Systematic Review: Comparative helpfulness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for improvidence principal hypertension.

Similar posts: diovan valsartan